SPOTLIGHT: GSK names Witty as new CEO
After a very long, very public selection process, GlaxoSmithKline has appointed Andrew Witty (photo), now president of the company's European pharma division, to succeed Jean-Pierre Garnier as CEO in May. Analysts said he'd been able to grow sales significantly in Europe despite pricing pressures--an ability that may help him in the U.S. as well. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
